These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 10379895)
1. Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. Lazennec G; Alcorn JL; Katzenellenbogen BS Mol Endocrinol; 1999 Jun; 13(6):969-80. PubMed ID: 10379895 [TBL] [Abstract][Full Text] [Related]
2. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells. Lazennec G; Katzenellenbogen BS Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022 [TBL] [Abstract][Full Text] [Related]
3. Repression of endogenous estrogen receptor activity in MCF-7 human breast cancer cells by dominant negative estrogen receptors. Ince BA; Schodin DJ; Shapiro DJ; Katzenellenbogen BS Endocrinology; 1995 Aug; 136(8):3194-9. PubMed ID: 7628351 [TBL] [Abstract][Full Text] [Related]
4. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. Girgert R; Hanf V; Emons G; Gründker C J Pineal Res; 2009 Aug; 47(1):23-31. PubMed ID: 19522736 [TBL] [Abstract][Full Text] [Related]
5. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Swami S; Krishnan AV; Feldman D Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825 [TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Jeng MH; Shupnik MA; Bender TP; Westin EH; Bandyopadhyay D; Kumar R; Masamura S; Santen RJ Endocrinology; 1998 Oct; 139(10):4164-74. PubMed ID: 9751496 [TBL] [Abstract][Full Text] [Related]
7. Dominant negative ER induces apoptosis in GH(4) pituitary lactotrope cells and inhibits tumor growth in nude mice. Lee EJ; Duan WR; Jakacka M; Gehm BD; Jameson JL Endocrinology; 2001 Sep; 142(9):3756-63. PubMed ID: 11517151 [TBL] [Abstract][Full Text] [Related]
8. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Pink JJ; Jordan VC Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307 [TBL] [Abstract][Full Text] [Related]
9. Loss of an estrogen receptor isoform (ER alpha delta 3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. Erenburg I; Schachter B; Mira y Lopez R; Ossowski L Mol Endocrinol; 1997 Dec; 11(13):2004-15. PubMed ID: 9415404 [TBL] [Abstract][Full Text] [Related]
10. Identification of genes involved in growth inhibition of breast cancer cells transduced with estrogen receptor. Licznar A; Caporali S; Lucas A; Weisz A; Vignon F; Lazennec G FEBS Lett; 2003 Oct; 553(3):445-50. PubMed ID: 14572667 [TBL] [Abstract][Full Text] [Related]
11. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. Jiang SY; Jordan VC J Natl Cancer Inst; 1992 Apr; 84(8):580-91. PubMed ID: 1556769 [TBL] [Abstract][Full Text] [Related]
12. Induction of estrogen-regulated genes differs in immortal and tumorigenic human mammary epithelial cells expressing a recombinant estrogen receptor. Zajchowski DA; Sager R Mol Endocrinol; 1991 Nov; 5(11):1613-23. PubMed ID: 1664044 [TBL] [Abstract][Full Text] [Related]
13. Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells. Hurd C; Dinda S; Khattree N; Moudgil VK Oncogene; 1999 Jan; 18(4):1067-72. PubMed ID: 10023683 [TBL] [Abstract][Full Text] [Related]
14. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Philips A; Teyssier C; Galtier F; Rivier-Covas C; Rey JM; Rochefort H; Chalbos D Mol Endocrinol; 1998 Jul; 12(7):973-85. PubMed ID: 9658402 [TBL] [Abstract][Full Text] [Related]
15. A transcriptionally active estrogen receptor mutant is a novel type of dominant negative inhibitor of estrogen action. McInerney EM; Ince BA; Shapiro DJ; Katzenellenbogen BS Mol Endocrinol; 1996 Dec; 10(12):1519-26. PubMed ID: 8961262 [TBL] [Abstract][Full Text] [Related]
16. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen. Morrissey JJ; Raney S Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849 [TBL] [Abstract][Full Text] [Related]
17. Characterization of stably transfected fusion protein GFP-estrogen receptor-alpha in MCF-7 human breast cancer cells. Zhao H; Hart LL; Keller U; Holth LT; Davie JR J Cell Biochem; 2002; 86(2):365-75. PubMed ID: 12112006 [TBL] [Abstract][Full Text] [Related]
18. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha. Kinoshita Y; Chen S Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940 [TBL] [Abstract][Full Text] [Related]
19. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Dubik D; Dembinski TC; Shiu RP Cancer Res; 1987 Dec; 47(24 Pt 1):6517-21. PubMed ID: 3677090 [TBL] [Abstract][Full Text] [Related]
20. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro. Reddel RR; Sutherland RL Cancer Res; 1987 Oct; 47(20):5323-9. PubMed ID: 3652038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]